Alicia Morgans, MD, MPH, and Paul Sieber, MD, introduce the discussion, outlining goals to connect evolving mCRPC research with personalized immunotherapy practice.
Transforming Advanced Prostate Cancer Care Through Personalized Immunotherapy and Real-World Insights
The experts discuss how recent therapeutic advances and trial data are reshaping standard care in advanced prostate cancer.
Healthcare professionals discuss adapting treatment guidelines based on genomic testing, emphasizing early detection and personalized care for high-risk patients.
Explore the complexities of treating mCRPC with personalized immunotherapies, addressing comorbidities and patient response challenges.
Experts discuss the importance of early treatment with Provenge for prostate cancer, highlighting patient demographics and response variability.
Long-term data on sipuleucel-T reveals significant survival benefits, emphasizing the importance of multiple lines of therapy in patient outcomes.
Experts discuss the importance of managing cardiovascular health and bone health in prostate cancer treatment, emphasizing real-world data and patient care strategies.
Experts discuss the importance and limitations of real-world evidence in assessing cardiovascular risks associated with ARPIs, emphasizing the need for critical analysis.
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: December 2025
2
Beyond the clinic: Physician presence on social media
3
Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions
4
Study validates Decipher as a predictor of early biochemical recurrence in prostate cancer
5